A Study to Confirm Recurrent or Persistent Cushing’s Syndrome in Patients With Signs or Symptoms of Hypercortisolemia

Overview

This is an observational study to confirm the presence of recurrent or persistent endogenous Cushing's syndrome in patients who have had primary surgical and/or radiation therapy for Cushing's disease and continue to manifest symptoms and signs of hypercortisolemia.

Full Title of Study: “A Study to Confirm the Presence of Recurrent or Persistent Cushing’s Syndrome in Patients With Clinical Signs or Symptoms of Hypercortisolemia Who Have Been Treated for Cushing’s Disease”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: June 2010

Interventions

  • Drug: Cushing’s syndrome confirmation

Arms, Groups and Cohorts

  • 1
    • Patients with presumed Cushing’s disease who have failed pituitary surgery and/or radiation and require medical treatment for recurrent or persistent Cushing’s syndrome.

Clinical Trial Outcome Measures

Primary Measures

  • To confirm the presence of recurrent or persistent endogenous Cushing’s syndrome in patients who have had primary surgical and/or radiation therapy for Cushing’s disease and continue to manifest symptoms and signs of hypercortisolemia.
    • Time Frame: up to 16 weeks

Participating in This Clinical Trial

Inclusion Criteria

  • Are at least 18 years of age. – Have a presumptive diagnosis of Cushing's disease (Cushing's syndrome due to an ACTH secreting pituitary tumor). – Have previously had pituitary surgery and/or pituitary radiation with the intent of curing or treating Cushing's disease. – Have clinical symptoms and signs of hypercortisolism. – Are able to provide written informed consent. – Are expected to complete the study. Exclusion Criteria:

  • Are surgical candidates for pituitary surgery or have had pituitary surgery within 8 weeks before screening. – Have taken any medication that may interfere with protocol testing procedures within 30 days of initial screening (phenobarbital, phenytoin, carbamazepine, oxcarabazepine, primidone, rifampin, rifapentine, rifabutin, ethosuximide, pioglitazone, efavirenz, neviparine, modafinil, St. Johns wort, glucorticoids, estrogen containing oral contraceptives). – Have received investigational treatment (drug, biologic agent or device) within 30 days of screening. – Have a non-endogenous source of hypercortisolemia such as factitious hypercortisolemia (exogenous source of glucocorticoid, iatrogenic Cushing's syndrome), factitious or therapeutic use of ACTH. – Have Pseudo-Cushing's syndrome. Subjects with suspected Pseudo-Cushing's syndrome such as those with severe obesity, major depression or a history of alcoholism. – Uncontrolled, clinically significant hypothyroidism or hyperthyroidism. – Have renal failure as defined by a serum creatinine of 202 mg/dL. – Elevated total bilirubin (>1.5x ULN), elevated ALT(>3x ULN) or AST (>3x ULN).

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Corcept Therapeutics
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Coleman Gross, MD, Study Director, Corcept Therapeutics

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.